Latest Distributions News

Invictus Energy has completed a key legal review and secured $12 million in funding, setting the stage for expanded drilling and development in Zimbabwe's Cabora Bassa Basin.

Multistack International Limited reported a net cash outflow from operating activities of $72,916 for the December 2024 quarter but ended with robust cash reserves of $975,608. Despite ongoing negative cash flows, the company remains confident in sustaining operations through secured financing and strategic asset acquisitions.

Pengana Private Equity Trust has updated the Dividend Reinvestment Plan (DRP) price for its upcoming ordinary distribution, maintaining a steady payout of AUD 0.03176 per unit for the half-year ending December 2024.

TMK Energy has successfully doubled its pilot production capacity at the Gurvantes XXXV Coal Seam Gas project and inked an early commercialisation deal to supply gas for power generation, positioning itself as a pioneer in Mongolia's emerging CSG sector.

Clarity Pharmaceuticals has secured a second FDA Fast Track Designation for its 64Cu-SAR-bisPSMA diagnostic agent, aiming to revolutionize prostate cancer imaging and speed regulatory approval.

Coventry Group reports a slight dip in H1 FY25 sales but manages a modest EBITDA increase, buoyed by a successful ERP upgrade and strategic growth initiatives.

Stockland updates its dividend distribution details, confirming an 8 cent per security payout and announcing the Dividend Reinvestment Plan price ahead of the February payment date.

RLF AgTech Ltd has retracted previously announced field trial results due to ASX compliance issues, while simultaneously reporting significant debt reduction and ongoing equity raising efforts to support its expanding Australian and Chinese operations.

CD Private Equity Fund II has announced a special unfranked dividend of AUD 0.09 per ordinary unit, payable on February 24, 2025, signaling steady returns for investors.

Biome Australia Limited has expanded its distribution footprint to over 6,000 health retail and practitioner locations, marking a 20% increase in six months and advancing toward its Vision 27 target of 8,000 sites by FY27.

Bioxyne Limited has raised its FY2025 revenue forecast to $25 million, driven by a remarkable 267% increase in first-half revenue and strong momentum from its subsidiary Breathe Life Sciences.

Memphasys Limited marks a pivotal quarter with the completion of clinical trials for its Felix™ System, strategic market expansions in Greater China and the Middle East, and a successful capital raise to fuel growth.